

(Use several sheets if necessary)

ATTY. DOCKET NO.
33687-US-PCT
APPLICATION NO.APPLICANT
FELDMAN ET AL.
FILING DATE

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/M.F./	AA	2003/0114389A1	6/19/03	Webb	514	19	
/M.F./	AB	2003/229007	12/11/03	Levi et al.	514	2	
/M.F./	AC	4,885,292	12/5/89	Ryono et al.	514	211	
/M.F./	AD	5,376,638	12/27/94	Young et al.	514	12	
/M.F./	AE	5,182,266	1/26/93	Kleinert	514	18	
/M.F./	AF	5,202,322	4/13/93	Allen et al.	514	228.2	
/M.F./	AG	5,821,232	10/13/98	Fossa	514	18	
	AH						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO
	AI	0-548-676-A2	12/16/92	EP			<input type="checkbox"/> <input type="checkbox"/>
	AD	0-570-652-A1	8/4/92	EP			<input type="checkbox"/> <input type="checkbox"/>
	AK	EP 1-342-379-A1	5/24/03	EP			<input type="checkbox"/> <input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AI	Allikmae, "Alogliken Speedel" Current Opinion in Investigational Drugs, Vol. 3, No. 10, pp 1479-1482, (2002)
AM	Azizi et al, "Pharmacologic Demonstration of the Synergistic Effects of combination of the Renin Inhibitor Alogliken and the AT1 Receptor Antagonist Valsartan on the Angiotensin II Renin Feedback Interruption." J. Am. Soc. Nephrol 15, pp. 3126-3133 (2004)
AN	Beers et al, The Merck Manual of diagnosis and Therapy, Seventeenth Edition XP002304176 (1999)
AO	Boger et al., "Dose-dependent effects on blood pressure and the renin-angiotensin system with a new orally active renin inhibitor." Clinical Pharmacology and Therapeutics, Vol. 53, no. 2, p. 140 (1993)
AP	Fossa et al, "Synergistic Effect on Reduction in Blood Pressure With coadministration of a Renin Inhibitor or an Angiotensin-Converting Enzyme Inhibitor With an Angiotensin II Receptor Antagonist" Drug Development Research 33, pp. 422-426 (1994)
AQ	Himmelman et al, "Remikren (Ro 42-5802) - An Orally Active Renin Inhibitor in Essential Hypertension" AII, Vol. 9, No. 6, pp. 517-522 (1996)
AR	Maibam et al, "Renin inhibitors as novel treatments for cardiovascular disease." Monthly Focus: Cardiovascular, Renal, Endocrine & Metabolic, Expert Opinion Ther. Patents No. 13(5),pp 599-600 (2003)

EXAMINER

/Meghan Finn/

DATE CONSIDERED

05/29/2009

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

(Use several sheets if necessary)

ATTY. DOCKET NO.
33687-US-PCT
APPLICATION NO.APPLICANT
FELDMAN ET AL.
FILING DATE

Group

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES <input type="checkbox"/> NO <input type="checkbox"/>
BA	WO 01/15673 A2	3/8/01	WO			
BB	WO 01/15674 A	3/8/01	WO			
BC	WO 03/005040 A2	5/1/03	WO			<input type="checkbox"/> <input type="checkbox"/>
BD	WO 03/007008 A1	11/27/03	WO			<input type="checkbox"/> <input type="checkbox"/>
BE	WO 03/000270 A1	12/4/03	WO			<input type="checkbox"/> <input type="checkbox"/>
BF	WO 03/000767 A1	12/4/03	WO			<input type="checkbox"/> <input type="checkbox"/>
BG	WO 02/10097	6/26/02	WO			<input type="checkbox"/> <input type="checkbox"/>
BH	WO 2004/002549 A1	1/8/04	WO			<input type="checkbox"/> <input type="checkbox"/>
BI	WO 2004/002957 A1	1/8/04	WO			<input type="checkbox"/> <input type="checkbox"/>
BJ	WO 2004/100871 A2	11/25/04	WO			<input type="checkbox"/> <input type="checkbox"/>
BK	WO 02/40007 A1	5/23/02	WO			<input type="checkbox"/> <input type="checkbox"/>
BL	WO 2005/029103 A2	5/17/05	WO			<input type="checkbox"/> <input type="checkbox"/>
BM	WO 2005/054244 A2	6/16/05	WO			<input type="checkbox"/> <input type="checkbox"/>
BN	WO 2005/070400	6/4/05	WO			<input type="checkbox"/> <input type="checkbox"/>
BO	WO 2005/077418 A1	6/25/05	WO			<input type="checkbox"/> <input type="checkbox"/>
BP						<input type="checkbox"/> <input type="checkbox"/>
BQ						<input type="checkbox"/> <input type="checkbox"/>
BR						<input type="checkbox"/> <input type="checkbox"/>
BS						<input type="checkbox"/> <input type="checkbox"/>
BT						<input type="checkbox"/> <input type="checkbox"/>
BU						<input type="checkbox"/> <input type="checkbox"/>
BV						<input type="checkbox"/> <input type="checkbox"/>
BW						<input type="checkbox"/> <input type="checkbox"/>
BX						<input type="checkbox"/> <input type="checkbox"/>
BY						<input type="checkbox"/> <input type="checkbox"/>
BZ						<input type="checkbox"/> <input type="checkbox"/>

EXAMINER

/Meghan Finn/

DATE CONSIDERED

05/29/2009

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.